Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRENE Study: Retifanlimab and Pelareorep in Metastatic TNBC
NCT04445844Phase 2Active, not recruiting
- Sponsor
- Mridula George
- Start
- Jul 2020
- Primary completion
- Jun 2025
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab, pelareorep in triple-negative breast cancer (TNBC), sponsored by Mridula George. Started Jul 2020; status: active, not recruiting.
02
Drugs
retifanlimabpelareorep
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04445844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445844.